Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 651 across all filing types
Latest filing 2019-09-04 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, special relationships, and pledge agreements for GemVax & Kael. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2019-09-04 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and special relationships of major shareholders. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2019-08-19 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often referred to as a 'Section 16' equivalent in the US) to report insider trading or changes in share ownership by company directors or major shareholders. Based on the provided filing categories, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-08-19 Korean
기타경영사항(특허권취득)(자율공시)(항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물(대만))
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent for anti-inflammatory peptides in Taiwan. It provides details on the patent name, content, patent holder, and acquisition date. Since this is a regulatory announcement of a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2019-08-14 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'GemVax & KAEL' covering the period from January 1, 2019, to June 30, 2019. It contains detailed corporate information, financial data, capital structure, and management details. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim/Quarterly Report (IR). H1 2019
2019-08-14 Korean
전환가액의조정(제12회차)
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (CB). It details the change in conversion price, the number of convertible shares, and the underlying calculation methodology based on market price fluctuations. This type of disclosure is a standard corporate action related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2019-08-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.